Bigul

ANUH PHARMA LTD. - 506260 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyANUH PHARMA LTD. 2CIN NO.L24230MH1960PLC011586 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NIL 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Hemant Auti Designation: Company Secretary and Compliance Officer EmailId: [email protected] Name of the Chief Financial Officer: Darshan Rampariya Designation: Chief Financial Officer EmailId: [email protected] Date: 28/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
28-04-2023
Bigul

ANUH PHARMA LTD. - 506260 - Compliance Certificate Pursuant To Regulation 7 (3) Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended March 31, 2023.

Please find enclosed the Compliance Certificate pursuant to Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended March 31, 2023. Request you to take the same on record.
14-04-2023
Bigul

ANUH PHARMA LTD. - 506260 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Regulation 74(5) of the SEBI (Depositories and Participants), Regulations, 2018 for the quarter ended 31st March, 2023
11-04-2023
Bigul

ANUH PHARMA LTD. - 506260 - Closure of Trading Window

Intimation of Trading Window Closure as per SEBI (Prohibition of Insider Trading) Regulations, 2015 for the quarter and year ended March 31, 2023.
31-03-2023
Bigul

ANUH PHARMA LTD. - 506260 - Announcement under Regulation 30 (LODR)-Investor Presentation

Investor Presentation - Q3 FY2023 Dear Sir/Madam, We are enclosing herewith our Company's Investor Presentation for Q3 FY2023. Kindly take the same on record. Thanking you,
17-02-2023
Bigul

ANUH PHARMA LTD. - 506260 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication of Unaudited Financial Results for the quarter ended 31.12.2022 Please find enclosed herewith the copy of newspaper advertisement with respect to the Unaudited Financial Results for the quarter ended December 31, 2022, published in the Financial Express and Mumbai Lakshadeep in compliance with Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kindly acknowledge the receipt and take the same on record. Thanking you,
17-02-2023
Bigul

ANUH PHARMA LTD. - 506260 - Announcement under Regulation 30 (LODR)-Resignation of Director

Pursuant to Regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) 2015, this is to inform you that Mr. Lalitkumar P Shah (DIN: 00396345) Non-Executive Director of the Company has vide his resignation letter dated 10th February 2023, resigned from the Board of the Company with immediate effect. The resignation letter with reason as indicated is enclosed.
10-02-2023
Bigul

ANUH PHARMA LTD. - 506260 - Submission Of Unaudited Financial Results For The Quarter Ended December 31, 2022 Along With Limited Review Report.

Pursuant to the provisions of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we are enclosing herewith the following: 1. Unaudited Financial Results for the quarter ended December 31, 2022; and 2. Limited Review Report for the quarter ended December 31, 2022. You are requested to kindly take the same on record.
10-02-2023
Bigul

ANUH PHARMA LTD. - 506260 - Board Meeting Outcome for Outcome Of Board Meeting Dated 10Th February, 2023.

Pursuant to the provisions of Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, this is to inform you that the Board of Directors of the Company (the "Board") at its Meeting held today i.e. Friday, 10th February, 2023, inter-alia considered and approved the following agenda Items: 1. The Un-Audited Financial Results along with Limited Review Report thereon for the quarter ended 31st December, 2022. 2. The Board has approved the Resignation of Mr. Lalitkumar P Shah from the post of Director of Anuh Pharma Limited with immediate effect. The Meeting of the Board of Directors commenced at 12:30 p.m. and concluded at 4:15 p.m
10-02-2023
Bigul

ANUH PHARMA LTD. - 506260 - Board Meeting Intimation for Prior Intimation Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

ANUH PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2023 ,inter alia, to consider and approve Pursuant to the provisions of Regulation 29(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Meeting of the Board of Directors of the Company is scheduled to be held on Friday, 10th February 2023, inter alia: 1) To consider and approve Unaudited Financial Results of the Company for the quarter ended 31st December, 2022; and 2) To consider any other matter with the permission of the Chairman.
03-02-2023
Next Page
Close

Let's Open Free Demat Account